Sign in

ELMD on NYSE

Electromed, Inc.

American electromedical and electrotherapeutic apparatus company1

In its 2026 annual report the company says: “Electromed, Inc. develops, manufactures, markets and sells innovative products that provide airway clearance therapy, including the SmartVest ® Airway Clearance System to patients with compromised pulmonary function with a commitment to excellence and compassionate service.”4 It is headquartered in New Prague, Minnesota.1 Its shares trade on NYSE under the symbol ELMD.1

Price unavailable

Last updated Oct 21, 2026.

Overview

$73.8MRevenue, fiscal 20262
$11.3MNet income, fiscal 20262

Compare with EDAP TMS SA, Ceribell, Inc. or VASO Corp, or pick any stock.

  • TickerELMD on NYSE1
  • IndustryElectromedical & Electrotherapeutic Apparatus1
  • HeadquartersNew Prague, Minnesota1
  • Incorporated inMN3
  • Business address500 Sixth Avenue Nw, New Prague, Mn 560713
  • Filer categoryNon-accelerated filer, Smaller reporting company3

See how the biggest companies compare on our leaderboards

Electromed, Inc. (“we,” “our,” “us,” “Electromed” or the “Company”) develops, manufactures, markets and sells innovative products that provide airway clearance therapy, including the SmartVest ® Airway Clearance System (“SmartVest System”) to patients with compromised pulmonary function with a commitment to excellence and compassionate service. Our goal is to make High Frequency Chest Wall Oscillation (“HFCWO”) treatments as effective, convenient, and comfortable as possible, so our patients can breathe easier and live better with improved respiratory function and fewer exacerbations.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

78.5%Gross margin2
18.8%Operating margin2
15.3%Net margin2
15.3%Revenue growth, 20262
20.9%Return on equity2
$8.4MFree cash flow2

Where the money goes

Where each dollar of revenue went, fiscal 2026

  • Cost of revenue21¢$15.8M
  • Research and development2¢$1.3M
  • Selling, general and admin58¢$42.7M
  • Income tax4¢$3.1M
  • Profit15¢$11.3M

Out of $73.8M in revenue.2

Where each dollar of operating cash went, fiscal 2026

  • Capital spending13¢$1.3M
  • Share buybacks41¢$3.9M
  • Kept or used elsewhere47¢$4.5M

Out of $9.7M of cash from operations.2

Financial statements

Revenue56789102$73.8M in 2026+136% since 2019
0$20.0M$40.0M$60.0M$80.0M2019: $31.3M$31.3M20192020: $32.5M$32.5M2020+4%2021: $35.8M$35.8M2021+10%2022: $41.7M$41.7M2022+17%2023: $48.1M$48.1M2023+15%2024: $54.7M$54.7M2024+14%2025: $64.0M$64.0M2025+17%2026: $73.8M$73.8M2026+15%
Gross profit56789102$57.9M in 2026+143% since 2019
0$20.0M$40.0M$60.0M2019: $23.8M$23.8M20192020: $25.2M$25.2M2020+6%2021: $27.3M$27.3M2021+8%2022: $31.4M$31.4M2022+15%2023: $36.5M$36.5M2023+16%2024: $41.7M$41.7M2024+14%2025: $50.0M$50.0M2025+20%2026: $57.9M$57.9M2026+16%
Operating income56789102$13.9M in 2026+391% since 2019
0$5.0M$10.0M$15.0M2019: $2.8M$2.8M20192020: $5.1M$5.1M2020+81%2021: $3.1M$3.1M2021−39%2022: $3.0M$3.0M2022−5%2023: $4.0M$4.0M2023+35%2024: $6.6M$6.6M2024+64%2025: $9.7M$9.7M2025+47%2026: $13.9M$13.9M2026+44%
Net income56789102$11.3M in 2026+471% since 2019
0$5.0M$10.0M$15.0M2019: $2.0M$2.0M20192020: $4.2M$4.2M2020+110%2021: $2.4M$2.4M2021−43%2022: $2.3M$2.3M2022−2%2023: $3.2M$3.2M2023+37%2024: $5.2M$5.2M2024+63%2025: $7.5M$7.5M2025+46%2026: $11.3M$11.3M2026+50%

Every line of the income statement as filed: the last 2 fiscal years, latest first.2

Period ending2026-06-302025-06-30
Net revenues$73.8M$64.0M
Cost of revenues$15.8M$14.0M
Gross profit$57.9M$50.0M
Selling, general and administrative$42.7M$39.3M
Research and development$1.3M$996.0K
Total operating expenses$44.1M$40.3M
Operating income$13.9M$9.7M
Interest income, net$479.0K$624.0K
Net income before income taxes$14.4M$10.3M
Income tax expense$3.1M$2.7M
Net income$11.3M$7.5M
Basic (in dollars per share)$1.37$0.89
Diluted (in dollars per share)$1.30$0.85
Basic (in shares)8.3M shares8.5M shares
Diluted (in shares)8.7M shares8.9M shares

Compare Electromed, Inc. with another company

Corporate structure

Electromed, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Electromed, Inc.

  • Electromed, Inc. New Prague, Minnesota

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Electromed, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$10.8M2 Jun 30, 2026$10.7M2 Jun 30, 2025+0.9%
Accumulated depreciation$5.6M2 Jun 30, 2026$6.0M2 Jun 30, 2025−6.8%
Property and equipment, net$5.2M2 Jun 30, 2026$4.7M2 Jun 30, 2025+10.6%
Operating-lease assets (leased space)$131.0K2 Jun 30, 2026$198.0K2 Jun 30, 2025−33.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$20.4M2 Jun 30, 2026$15.3M2 Jun 30, 2025+33.8%

Intangibles and goodwill

ItemLatestA year beforeChange
Accumulated amortization$487.0K2 Jun 30, 2026$428.0K2 Jun 30, 2025+13.8%
Finite-lived intangibles, net$379.0K2 Jun 30, 2026$371.0K2 Jun 30, 2025+2.2%

Inventory

ItemLatestA year beforeChange
Inventory, total$3.7M2 Jun 30, 2026$3.3M2 Jun 30, 2025+11.6%
Work in process$211.0K2 Jun 30, 2026$180.0K2 Jun 30, 2025+17.2%
Finished goods$772.0K2 Jun 30, 2026$928.0K2 Jun 30, 2025−16.8%

Properties, in its own words

We own our principal headquarters and manufacturing facilities, consisting of approximately 37,000 square feet, which are located on an approximately 2.3-acre parcel in New Prague, Minnesota. Nearly all the Company’s revenues, profits, and assets are associated with this facility. We believe that our facilities are satisfactory for our long-term growth plans.

Item 2 of the 10-K filed Aug 25, 2026.4

Leadership

Who has led Electromed, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Robert D. Hansen2010–2011
  2. Kathleen Skarvan2012–2023
  3. James L. Cunniff2023–now

President

  1. Kathleen Skarvan2015–2023
  2. James L. Cunniff2023–now

Chief financial officer

  1. Terry M. Belford2010–2011
  2. Jeremy T. Brock2012–2020
  3. Kathleen Skarvan2015
  4. Michael Joseph Maccourt2020–2021
  5. Michelle C. Wirtz2022
  6. Bradley M. Nagel2022–now

Chief operating officer

  1. James J. Cassidy2011–2012
201520202025
Board members and other officers (20)

Timeline

  1. Aug 25, 20268-K Results of operations; Executive or director change; Regulation FD disclosure42
  2. May 12, 20268-K Results of operations; Regulation FD disclosure43
  3. Feb 10, 20268-K Results of operations; Regulation FD disclosure44
  4. Dec 18, 20258-K Entered a material agreement; New debt or obligation45
  5. Nov 18, 20258-K Shareholder vote46
  6. Nov 12, 20258-K Results of operations; Regulation FD disclosure47
  7. Sep 9, 20258-K Regulation FD disclosure; Other events48
  8. Aug 26, 20258-K Results of operations; Regulation FD disclosure49
  9. May 13, 20258-K Results of operations; Regulation FD disclosure50
  10. Mar 10, 20258-K Regulation FD disclosure; Other events51
  11. Feb 11, 20258-K Results of operations; Regulation FD disclosure52
  12. Nov 18, 20248-K Bylaws or fiscal year changed; Shareholder vote53
  13. Jul 5, 2023New chief executive James L. Cunniff becomes CEO13
  14. Dec 4, 2012New chief executive Kathleen Skarvan becomes CEO14
  15. Aug 12, 2010New chief executive Robert D. Hansen becomes CEO15

Calendar

Coming up

  1. Nov 11, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.25 a share, on Nov 12, 2025.54

When it reported results

  1. Aug 25, 2026Reported quarterly or annual results42
  2. May 12, 2026Reported quarterly or annual results43
  3. Feb 10, 2026Reported quarterly or annual results44
  4. Nov 12, 2025Reported quarterly or annual results47
  5. Aug 26, 2025Reported quarterly or annual results49
  6. May 13, 2025Reported quarterly or annual results50
  7. Feb 11, 2025Reported quarterly or annual results52
  8. Nov 12, 2024Reported quarterly or annual results55

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

182 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 37 major events, 74 insider forms, 16 large holders, 35 other. The latest 20:

  1. Sep 29, 2026DEF 14A EDGAR
  2. Sep 29, 2026DEFA14A EDGAR
  3. Sep 29, 2026ARS EDGAR
  4. Sep 3, 20264 EDGAR
  5. Sep 3, 20264 EDGAR
  6. Aug 25, 20268-K EDGAR
  7. Aug 25, 202610-K EDGAR
  8. Jul 2, 20264 EDGAR
  9. Jun 9, 20264 EDGAR
  10. Jun 8, 2026144 EDGAR
  11. Jun 8, 20264 EDGAR
  12. Jun 4, 2026144 EDGAR
  13. May 29, 2026SD EDGAR
  14. May 19, 20264 EDGAR
  15. May 15, 2026144 EDGAR
  16. May 12, 202610-Q EDGAR
  17. May 12, 20268-K EDGAR
  18. Apr 1, 2026UPLOAD EDGAR
  19. Mar 26, 2026SCHEDULE 13G/A EDGAR
  20. Mar 25, 2026CORRESP EDGAR

The 182 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

20 open-market trades by officers, directors and large owners since October 2021: 3 buys and 17 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 8, 2026Cunniff James L.CEO and PresidentSale9,700$36.51$354.1KForm 4
Jun 4, 2026Nagel Bradley M.Chief Financial OfficerSale11,801$36.35$429.0KForm 4
May 15, 2026SKARVAN KATHLEENDirectorSale40,000$35.48$1.4MForm 4
Sep 11, 2025Summers AndrewDirectorSale3,153$24.42$77.0KForm 4
Sep 10, 2025Summers AndrewDirectorSale62,561$24.32$1.5MForm 4
Feb 24, 2025Summers AndrewDirectorSale50,751$27.30$1.4MForm 4
Feb 21, 2025Summers AndrewDirectorSale25,451$28.21$717.9KForm 4
Feb 20, 2025Summers AndrewDirectorSale35,273$28.83$1.0MForm 4
Feb 18, 2025SKARVAN KATHLEENDirectorSale43,954$29.27$1.3MForm 4
Feb 14, 2025SKARVAN KATHLEENDirectorSale32,629$32.12$1.0MForm 4
Dec 5, 2024Summers AndrewDirectorSale37,404$28.15$1.1MForm 4
Dec 4, 2024Summers AndrewDirectorSale12,731$29.98$381.7KForm 4
Dec 3, 2024Summers AndrewDirectorSale35,436$30.18$1.1MForm 4
Dec 2, 2024Summers AndrewDirectorSale17,463$30.09$525.5KForm 4
Nov 19, 2024SKARVAN KATHLEENDirectorSale107,547$27.95$3.0MForm 4
Nov 18, 2024SKARVAN KATHLEENDirectorSale42,453$28.16$1.2MForm 4
Mar 1, 2024Cunniff James L.CEO and PresidentBuy9,000$15.25$137.2KForm 4
Dec 14, 2023Summers AndrewDirectorBuy28,797$10.50$302.4KForm 4
Nov 21, 2023Cunniff James L.CEO and PresidentBuy1,000$10.56$10.6KForm 4
Jul 12, 2023SKARVAN KATHLEENDirectorSale1,107$10.83$12.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2026James L. CunniffPresident and Chief Executive Officer$536.8K$1.8M64
2026Bradley M. NagelChief Financial Officer$335.5K$836.2K64
2025James L. CunniffPresident and Chief Executive Officer$519.2K$1.5M64
2025Bradley M. NagelChief Financial Officer$323.3K$756.7K64

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
J.E. Simmons & Co., P.C.483,822$20.5M11.5%−9,000
BlackRock, Inc.465,619$19.7M0.0%+6,774
Vanguard Capital Management LLC283,232$12.0M0.0%−51,796
Punch & Associates Investment Management, Inc.218,520$9.2M0.5%−6,000
Geode Capital Management, LLC217,115$9.2M0.0%+15,222
Dimensional Fund Advisors LP180,447$7.6M0.0%+2,177
Two Sigma Investments, LP167,492$7.1M0.0%−36,108
Gamco Investors, Inc. Et Al142,000$6.0M0.1%No change
State Street Corp112,616$4.8M0.0%+6,253
Renaissance Technologies LLC99,704$4.2M0.0%−24,300
Lazard Asset Management LLC93,472$4.0M0.0%−1,741
Vanguard Portfolio Management LLC84,297$3.6M0.0%+5,960
Northern Trust Corp84,138$3.6M0.0%−8,150
Goldman Sachs Group Inc72,704$3.1M0.0%+195
White Pine Capital LLC70,000$3.0M0.7%−65,228
Arrowstreet Capital, Limited Partnership66,798$2.8M0.0%+17,367
Bridgeway Capital Management, LLC57,563$2.4M0.0%−7,000
Invesco Ltd.51,394$2.2M0.0%New
Vanguard Fiduciary Trust Co49,731$2.1M0.0%+2,109
Bank of New York Mellon Corp46,022$1.9M0.0%+1,766
Morgan Stanley45,180$1.9M0.0%−784
Raymond James Financial Inc44,695$1.9M0.0%+1,426
Bnp Paribas Financial Markets43,015$1.8M0.0%+3,864
Ameriprise Financial Inc42,343$1.8M0.0%−3,221
Citadel Advisors LLC42,045$1.8M0.0%+22,584

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Electromed, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARElectromed, Inc.1
  • CIK0001488917
  • Employer ID (EIN)41-17329204
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inMinnesota4
  • Fiscal year endsJune 301
  • Industry code (SIC)3845 Electromedical & Electrotherapeutic Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address500 Sixth Avenue Nw, New Prague, MN 560711
  • Phone952-758-92991
  • Shares outstanding8,366,163 shares as of Aug 19, 20264
  • Public float$223.7M as of Dec 31, 20254
  • AuditorRSM US LLP, Minneapolis, Minnesota PCAOB ID 49; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceMay 3, 20101
  • Filings578 in all: 4 (181), 8-K (139), 10-Q (48), 3 (27), SC 13G/A (21), 10-K (17), DEF 14A (17), CORRESP (15)1
    All 40 form types

    DEFA14A (12), SD (12), SC 13G (11), 144 (10), UPLOAD (10), SC 13D/A (9), ARS (7), S-8 (5), S-1/A (4), SC 13D (4), FWP (3), 10-K/A (2), 4/A (2), 8-A12B (2), 8-K/A (2), PRER14A (2), 144/A (1), 25 (1), 3/A (1), 424B4 (1), 5 (1), CERTNAS (1), CERTNYS (1), EFFECT (1), NO ACT (1), PRE 14A (1), PREC14A (1), S-1 (1), S-8 POS (1), SCHEDULE 13D/A (1), SCHEDULE 13G (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (10-K) Aug 25, 2026
    Quarterly report (10-Q) May 12, 2026
    Proxy statement (DEF 14A) Sep 29, 2026
    Latest 8-K (8-K) Aug 25, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.01 per shareELMDNYSE American

From the cover page of the 10-K filed Aug 25, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

Legal proceedings

Occasionally, we may be party to legal actions, proceedings, or claims in the ordinary course of business, including claims based on the assertions of patent and trademark infringement. Corresponding costs are accrued when it is probable that loss will be incurred, and the amount can be precisely or reasonably estimated. We are not aware of any undisclosed actual or threatened litigation, other than ordinary routine litigation incidental to our business, that would have a material adverse effect on our financial condition or results of operations.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64